A. Marcos

467 total citations
10 papers, 360 citations indexed

About

A. Marcos is a scholar working on Infectious Diseases, Epidemiology and Surgery. According to data from OpenAlex, A. Marcos has authored 10 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 6 papers in Epidemiology and 4 papers in Surgery. Recurrent topics in A. Marcos's work include Antifungal resistance and susceptibility (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers) and Renal Transplantation Outcomes and Treatments (2 papers). A. Marcos is often cited by papers focused on Antifungal resistance and susceptibility (3 papers), Pneumocystis jirovecii pneumonia detection and treatment (3 papers) and Renal Transplantation Outcomes and Treatments (2 papers). A. Marcos collaborates with scholars based in United States, Spain and Italy. A. Marcos's co-authors include Stephen J. Bahr, Rolley E. Johnson, Thomas E. Starzl, Ron Shapiro, John J. Fung, Richard L. Simmons, Kenan Keven, Alakananda Basu, Kelong Han and Shahid Husain and has published in prestigious journals such as SHILAP Revista de lepidopterología, Antimicrobial Agents and Chemotherapy and Social Forces.

In The Last Decade

A. Marcos

10 papers receiving 333 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Marcos United States	6	195	116	109	53	48	10	360
Pamela Dole United States	10	199 1.0×	165 1.4×	29 0.3×	126 2.4×	32 0.7×	12	449
Ofole Mgbako United States	11	91 0.5×	145 1.3×	60 0.6×	48 0.9×	25 0.5×	30	227
Martha E. Gagliano United States	4	132 0.7×	35 0.3×	20 0.2×	107 2.0×	13 0.3×	5	360
Steven Huettner United States	13	274 1.4×	121 1.0×	111 1.0×	165 3.1×	88 1.8×	38	498
Leah M. Varga United States	10	191 1.0×	201 1.7×	118 1.1×	126 2.4×	71 1.5×	11	328
Penny Goold United Kingdom	8	73 0.4×	70 0.6×	53 0.5×	83 1.6×	28 0.6×	12	334
Lawrence O. Bryant United States	10	150 0.8×	100 0.9×	77 0.7×	93 1.8×	33 0.7×	18	370
Aseel Hegazi United Kingdom	10	287 1.5×	336 2.9×	111 1.0×	76 1.4×	101 2.1×	19	483
Claire Edmundson United Kingdom	8	256 1.3×	151 1.3×	67 0.6×	31 0.6×	78 1.6×	17	353
Shan-Estelle Brown United States	11	144 0.7×	106 0.9×	82 0.8×	61 1.2×	35 0.7×	23	292

Countries citing papers authored by A. Marcos

Since Specialization

Citations

This map shows the geographic impact of A. Marcos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Marcos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Marcos more than expected).

Fields of papers citing papers by A. Marcos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Marcos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Marcos. The network helps show where A. Marcos may publish in the future.

Co-authorship network of co-authors of A. Marcos

This figure shows the co-authorship network connecting the top 25 collaborators of A. Marcos. A scholar is included among the top collaborators of A. Marcos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Marcos. A. Marcos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Knobel, Hernando, Esperanza Cañas‐Ruano, Ana Guelar, et al.. (2023). Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study. SHILAP Revista de lepidopterología. 24(1). 2239564–2239564. 5 indexed citations

Perrella, Alessandro, et al.. (2012). Role of Liposomal Amphotericin B Prophylaxis After Liver Transplantation Compared With Fluconazole for High-Risk Patients. Impact on Infections and Mortality Within one Year. Transplantation Proceedings. 44(7). 1977–1981. 12 indexed citations

Perrella, Alessandro, et al.. (2012). Universal Oral Itraconazole Prophylaxis in Liver Transplantation: Boostering Immunosuppressive Drugs While Protecting from Fungal Infection. Transplantation. 94(10S). 394–394. 1 indexed citations

Johnson, Heather, Kelong Han, Blair Capitano, et al.. (2009). Voriconazole Pharmacokinetics in Liver Transplant Recipients. Antimicrobial Agents and Chemotherapy. 54(2). 852–859. 39 indexed citations

Shapiro, Ron, Demetrius Ellis, Michael L. Moritz, et al.. (2007). Alemtuzumab Pre-Conditioning With Tacrolimus Monotherapy in Pediatric Renal Transplantation. American Journal of Transplantation. 7(12). 2736–2738. 34 indexed citations

Keven, Kenan, Alakananda Basu, A. Marcos, et al.. (2004). Clostridium difficile colitis in patients after kidney and pancreas–kidney transplantation. Transplant Infectious Disease. 6(1). 10–14. 73 indexed citations

Basu, Amit, Ramkumar Mohan, Aslam Khan, et al.. (2004). REVERSAL OF RENAL ACUTE CELLULAR REJECTION(ACR) USING THE MONOCLONAL ANTIBODY CAMPATH 1H(C 1H). Transplantation. 78. 282–282. 1 indexed citations

Marcos, A., et al.. (1994). [Splenic abscess, a diagnostic and therapeutic problem].. PubMed. 47(4). 221–5. 3 indexed citations

Collazos, J., et al.. (1993). [Psoas abscess. The diagnostic and therapeutic considerations in 5 patients].. PubMed. 192(3). 123–6. 5 indexed citations

10.

Marcos, A., Stephen J. Bahr, & Rolley E. Johnson. (1986). Test of a Bonding/Association Theory of Adolescent Drug Use. Social Forces. 65(1). 135–161. 187 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact